Biotech marketing for the years before revenue.
Your science is real, but the balance sheet does not know it yet. Before there is a product to sell, your customers are the investors and partners who fund the next milestone, and they back the programs they can see and trust. D3 Digital Media installs the owned system that makes your program and your team visible to the people who write the checks and sign the deals.
Book a Strategy Call See how WAVES works How to market a biotech company →Great science does not fund itself.
A founder-led or clinical-stage biotech usually has the hardest part handled: a mechanism worth pursuing, early data that holds up, and a team that can defend every figure in the deck. What it almost never has is a repeatable way to make that program visible to the people who decide its future. Before there is revenue, the founder's own network is the fundraising engine and the partnering engine at the same time, and that network caps out fast. Every warm introduction spends down a finite list of relationships.
Investors, business development leads, and pharma partners back companies they can see and trust. Today that trust gets built the way it always has, in person, by the founder, one meeting at a time. That is the most expensive channel you own and it does not scale, and it goes quiet the moment the founder is buried in a data readout, an IND, or a raise. Meanwhile the people you have not met yet are running diligence the modern way. They search your name, they read what turns up, and increasingly they ask an AI assistant to summarize your company, and they find a thin website and a founder who has been too busy doing the science to be found doing it.
Investors do not fund the science they cannot see. Before revenue, being visible to the right people is not marketing polish. It is the difference between a term sheet and a maybe.
The help most biotechs can afford is the wrong help.
Agencies that do not grasp the science
They produce volume and chase impressions, and they write copy that a scientific reviewer will not respect and a serious investor will not read twice. You end up teaching them the field, then rewriting what they hand back. The output is quick, generic, and forgettable, and it does nothing to move a diligence conversation.
PR firms whose coverage stops when the check does
A placement in the right outlet feels like progress, and it can help. But PR spend evaporates the moment you pause the retainer. You rent attention for as long as you pay, and when the round is tight and you cut the line item, the visibility disappears with it. You own none of it.
What to bring to a biotech digital marketing engagement
Bring one decision your audience needs to make next. For a strategic partner, that might be whether your platform fits its research priorities. For an investor, it might be whether to ask for a meeting about a program milestone. That decision gives your marketing partner a concrete starting point.
- Bring a source your team can share. A publication, public presentation, or approved program summary gives the team evidence to work from and shows what still needs clarification.
- Name the scientific reviewer. Agree on who checks that a page explains the evidence accurately and who signs off before publication.
- Agree what you will measure. Pair visibility for relevant searches with actions such as visits to a program page or qualified partner inquiries.
Biotech needs a third option: an owned system that compounds. Something built on your own site and search footprint, structured for how investors and AI tools actually run diligence, that keeps working and keeps ranking whether or not you spent this month. That is what WAVES is.
The WAVES operating system, tuned for a pre-revenue biotech.
WAVES is five capabilities that compound into one loop. Each is adapted to the fact that your buyers, for now, are the investors and partners who fund and advance the program. You choose how much you run yourself with Coaching, or have our team run for you with WAVES Managed.
Web Presence
The site and search footprint an investor or partner hits during diligence, built to answer the questions they actually ask about the program, the data, and the team, and structured so AI tools summarize your science accurately instead of guessing.
Authority
Search optimization, evidence-led content, third-party visibility, and podcast guesting that puts your program in the rooms where funders and partners already are, so your credibility arrives before the first meeting does.
Voice
A captured voice profile for the founder and the scientists, so everything sounds like your team and stays inside the claims your data can actually support. No overstatement, no hedged mush.
Engagement
A daily rhythm that surfaces the investors, partners, and business development contacts signalling interest, so the founder's scarce outreach time lands on the few relationships that can move the raise or the deal.
Systems
A shared calendar, a CRM tracking the relationships that matter, and a weekly scoreboard, so who is watching, who is warming, and what is landing are measured rather than remembered.
One conversation becomes a month of visibility with funders.
The engine is built so the founder's scarcest resources, time and scientific judgment, produce the most output for the least effort. Here is the loop.
We capture the thinking
A recorded interview with the founder or a designated scientist. This is the only real time ask, usually a few hours a month, and it is the raw material for everything downstream. It is drawn from the same method behind the Life Science Success interviews.
We turn it into assets
Each conversation becomes a long-form article written for search and AI answers, short clips, posts, and, where it fits, a full episode. Evidence-led and written for a scientific reader, never overstated.
Your team stays in control
Nothing publishes without your review. You keep final say on every claim, so the message stays inside what the data supports and nothing goes out that you would not defend in a partnering meeting.
It compounds
Published work keeps ranking and keeps getting found, unlike PR spend that stops the day you pause it. The weekly scoreboard shows what is landing, and the quarterly checkup resets the plan against the next milestone.
An owned system, not a retainer you rent.
- A search-ready web presence that answers what investors and partners actually look for during diligence.
- A footprint built for AI diligence, so when a partner asks an assistant to summarize you, it cites your science correctly.
- A captured voice profile for the founder and the scientists, so the program sounds like your team and stays inside supportable claims.
- A steady stream of evidence-led content and podcast visibility that puts the program in front of the right rooms.
- A CRM and a weekly scoreboard tracking the investors, partners, and business development relationships that move the company.
- A quarterly checkup that resets priorities against your next milestone and next raise.
Founder-led and clinical-stage biotech.
The fit is a company where one leader still owns the decision and is willing to be in the strategic conversation, where the science is real, and where visibility with investors and partners is the constraint on the next stage. Companies that already have revenue and a team member with time to run the work usually run this as Coaching. Pre-revenue and clinical-stage companies usually run it as WAVES Managed, because they need investor and partner visibility now and do not yet have the internal team to build it.
If you are still hunting for your lead asset or your indication, that is a different job, and we will say so on the call rather than sell you a system you are not ready to run.
The honest answers.
We are pre-revenue and clinical-stage. Is marketing worth it yet?
Often yes, on WAVES Managed. Before there is a product to sell, your real buyers are the investors and partners who fund the next milestone, and they back programs they can see and trust. Managed is built to make your science and your team visible to those people while the founder stays focused on the program.
Do you actually understand biotech, or will we be teaching you?
We are led by an operator and advised by people who have built enterprise systems for life science organizations, and through the Life Science Success interviews we have sat with hundreds of leaders across the field. We do not need you to teach us the science to build the system, and the founder's own captured voice carries the technical detail.
How is this different from hiring a biotech PR firm?
PR chases coverage on a retainer, and that coverage stops the day you pause the spend. WAVES installs an owned, compounding system that you keep: your site, your search presence, your voice, and a repeatable rhythm. Published work keeps ranking and getting found whether or not you spent this month.
Will this actually help us get in front of investors and partners?
That is the point of it. The system is tuned so that when an investor or business development lead diligences you by search or by AI summary, they find a clear, accurate, credible picture of the program instead of a thin site. Engagement and the CRM then surface the ones signalling interest, so the founder's outreach time lands where it matters.
How much of the founder's time does this take?
On WAVES Managed, usually a few hours a month on camera for interviews, plus someone on your team to review content before it publishes. We handle production, publishing, and the systems. On Coaching, you build it with weekly guidance.
What does it cost?
There are two ways to run WAVES. Coaching is the build-it-yourself path that starts with the Onboarding Sprint. WAVES Managed is done-for-you, scoped to your company, and starts with a 90-day pilot. We walk you through pricing on a strategy call.
What is biotech marketing?
Biotech marketing is the work of making a company's science visible and credible to the people who decide its future. For most biotech companies those people are investors, partners, and eventually regulators and buyers, not a mass consumer audience. It covers your web presence, your published evidence, the founder's voice, and the systems that keep them current. D3 Digital Media treats it as an owned operating layer, built with WAVES, rather than a set of campaigns you rent.
How is biotech marketing different from pharmaceutical marketing?
The main difference is the buyer and the stage. Biotech marketing usually runs before there is an approved product, so the audience is investors, partners, and the scientific community watching your data. Pharmaceutical marketing more often supports an approved therapy moving to prescribers and patients inside heavy promotional regulation. Both reward evidence over claims that outrun it, but biotech leans on program credibility and the founder's authority while the company is still proving the science.
When should a founder-led biotech start marketing?
Earlier than most founders think. The moment you have data worth talking about, you have something worth making visible. For a clinical-stage biotech that usually means a first readout, a new preprint, or a partnership conversation on the horizon. This is not demand generation, it is the visibility and credibility that investors and partners check before they engage. WAVES installs that as a system you run, not a campaign you buy.
How do you market a pre-revenue or clinical-stage biotech to investors and partners?
You make the program legible before anyone asks for a meeting. That means a web presence that states the science clearly, an evidence library a diligence team can actually read, and the founder's voice on the thesis and the data. WAVES organizes this so that when an investor or business development lead searches you or asks an AI tool about you, they find an accurate, current picture. Engagement and the CRM then surface who is paying attention, so outreach time is spent well.
See what visibility would do for your next raise.
A working conversation, no pitch deck, no upsell. We will map where your program is invisible to the investors and partners who matter, and what the operating layer would change, specific to your company.
Book a Strategy Call Life sciences marketing →